Pharma BD Deal Intelligence
Crucell's all-stock acquisition of Berna Biotech built the promised "leading independent vaccine company," with Berna-derived products like Quinvaxem and Epaxal driving the majority of revenue and 38% YoY growth by 2008. J&J validated the thesis, paying a 58% premium for Crucell five years later, though a 2010-2011 manufacturing quality lapse forced a €22.8M inventory writedown.
Berna's vaccines and manufacturing base turned Crucell into a takeover target J&J paid a 58% premium for five years later
Full analysis, sources & comparables →Julius Bar analyst: 'It is the best that could have happened to Berna shareholders. The negative point we'd see in this transaction is the missing cash part.'…
Crucell's CHF 591M offer for Berna at a 20% premium positions the combined company to compete with Novartis/Chiron, Merck, GSK and Sanofi-Aventis as global…
The 2006 combination of Crucell, Berna Biotech, and SBL Vaccines created the sixth-largest vaccine company worldwide; Crucell was acquired by J&J in 2011.
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Vaccines; all-share deal CHF 591M, created leading independent vaccine company
Berna's vaccines and manufacturing base turned Crucell into a takeover target J&J paid a 58% premium for five years later
Assessment window: 15yr post-close.
The vaccine category covers infectious-disease prophylaxis spanning routine pediatric immunization, travel medicine (typhoid, hepatitis A, yellow fever), and seasonal influenza. Collectively these are among the highest-volume biologics globally, and at the 2005-2006 deal window the segment was forecast to grow rapidly as governments and pharma reinvested in pandemic and pediatric platforms.
The 2005-2006 vaccine industry was rapidly consolidating around four scaled players: Sanofi Pasteur (Sanofi-Aventis), GlaxoSmithKline, Merck, and Novartis (post-Chiron acquisition). Independent mid-cap vaccine houses faced an existential scale problem. Crucell (Netherlands) brought the proprietary PER.C6 cell-line manufacturing platform plus preclinical candidates in Ebola, malaria, influenza, and West Nile. Berna Biotech (Switzerland) brought marketed franchises in oral typhoid (Vivotif), hepatitis A (Epaxal), hepatitis B, and seasonal influenza, plus Phase III candidates in yellow fever and Pseudomonas aeruginosa. The all-share deal — CHF 591M (~$450M, 0.447 Crucell shares per Berna share, 27.3% premium) — created what both companies described as 'the leading independent vaccine company,' combining marketed revenue with a broad pipeline. Strategic logic: gain commercial scale to compete against Big Vaccine, integrate Berna's Swedish SBL Vaccin and Berna Products US footprint, and offer governments a non-Big-4 supplier for travel and pediatric biologics. Crucell itself was ultimately acquired by Johnson & Johnson in 2011, becoming Janssen Vaccines.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Crucell N.V. / Berna Biotech AG (this deal) | 2006 | $450M | 85 |
| Boehringer Ingelheim International GmbH / Sanofi SA (Merial Animal Health) | 2015 | $12.4B | 81 |
| Pfizer Inc. / Baxter International Inc. (commercial vaccines portfolio) | 2014 | $635M | 77 |
| GSK plc / Affinivax Inc. | 2022 | $3.3B | 48 |
| Novavax Inc. / Praha Vaccines | 2020 | $167M | 48 |
| Johnson & Johnson / Crucell N.V. | 2010 | $2.4B | 47 |
| Takeda Pharmaceutical Company Ltd. / Novavax Inc. | 2021 | $350M | — |
← Browse all deals · How we score deals
More: 2006 deals · Vaccines deals